VOYAGE phase 3: Dupilumab significantly reduced asthma exacerbations in children age 6-11
byAmerican Thoracic SocietyCredit: CC0 Public DomainResults from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages
Updated on: March 02,2024
13
VOYAGE phase 3: Dupilumab significantly reduced asthma exacerbations in children age 6-11
byAmerican Thoracic SocietyCredit: CC0 Public DomainResults from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages
Updated on:March 02,2024
13
